Ghost Tree Capital’s Rigel Pharmaceuticals RIGL Stock Holding History

Ghost Tree Capital’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-82,500	Closed	-$3.2M	–	62
2017 Q4	$3.2M	Sell	82,500 -27,500	-25%	-$1.05M	0.75%	39
2017 Q3	$2.79M	Hold	110,000	–	–	0.59%	51
2017 Q2	$3M	Hold	110,000	–	–	0.62%	53
2017 Q1	$3.64M	Buy	110,000 +40,000	+57%	+$1.02M	0.68%	50
2016 Q4	$1.67M	Hold	70,000	–	–	0.4%	57
2016 Q3	$2.57M	Sell	70,000 -10,000	-13%	-$287K	0.42%	63
2016 Q2	$1.78M	Buy	+80,000	New	+$1.99M	0.52%	47

Other funds holding RIGL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Ghost Tree Capital's RIGL Position: Q1 2018 in Review

Ghost Tree Capital sold out of Rigel Pharmaceuticals (RIGL) in Q1 2018, closing a stake of 82,500 shares — an estimated $3.2M sold.

Ghost Tree Capital first reported a position in RIGL in Q2 2016 and held it in 7 quarters. The position peaked at $3.64M in Q1 2017. 117 funds tracked by Wall St. Rank hold RIGL as of Q1 2018.

Ghost Tree Capital reported no remaining Rigel Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Ghost Tree Capital sold 82,500 Rigel Pharmaceuticals shares in Q1 2018, an estimated $3.2M.
Ghost Tree Capital first reported a position in Rigel Pharmaceuticals in Q2 2016 and held it in 7 quarters.
Ghost Tree Capital's Rigel Pharmaceuticals position peaked at $3.64M in Q1 2017.
117 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2018.

Based on Ghost Tree Capital's 13F filing for Q1 2018, filed 15 May 2018.